We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

86 hedge funds and large institutions have $727M invested in Revance Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

68% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 22

33% more capital invested

Capital invested by funds: $546M → $727M (+$180M)

10% more funds holding

Funds holding: 78 → 86 (+8)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

15% less call options, than puts

Call options by funds: $776K | Put options by funds: $909K

Holders
86
Holders Change
+8
Holders Change %
+10.26%
% of All Funds
2.14%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
37
Reduced
22
Closed
4
Calls
$776K
Puts
$909K
Net Calls
-$133K
Net Calls Change
-$471K

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$8.73M
2
Jennison Associates
Jennison Associates
New York
+$8.44M
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$5.84M
4
JP Morgan Chase
JP Morgan Chase
New York
+$3.72M
5
PC
PointState Capital
New York
+$3.61M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$8.23M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.53M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.39M
4
Wells Fargo
Wells Fargo
California
-$1.07M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$735K
Name Holding Trade Value Shares
Change 		Change in
Stake
Creative Planning
76
Creative Planning
Kansas
$26K +$20.1K +900 +900%
TRCT
77
Tower Research Capital (TRC)
New York
$16K +$13.4K +600 New
UBS Group
78
UBS Group
Switzerland
$13K +$11.1K +500 +4,545%
Zurich Cantonal Bank
79
Zurich Cantonal Bank
Switzerland
$10K – – –
PAM
80
Panagora Asset Management
Massachusetts
$10K +$8.72K +391 New
Citigroup
81
Citigroup
New York
$6K -$1.63K -73 -23%
HNB
82
Huntington National Bank
Ohio
$6K – – –
WAS
83
Winch Advisory Services
Wisconsin
$5K – – –
BRC
84
Bell Rock Capital
Delaware
$3K – – –
QCG
85
Quadrant Capital Group
Ohio
$2K – – –
Envestnet Asset Management
86
Envestnet Asset Management
Illinois
$1K – – –
Acadian Asset Management
87
Acadian Asset Management
Massachusetts
– -$735K -35,338 Closed
CM
88
Crestline Management
Texas
– -$520K -25,000 Closed
EMG
89
Ellington Management Group
Connecticut
– -$341K -16,400 Closed
MAM
90
Meeder Asset Management
Ohio
– -$11K -505 Closed
1 2 3
4

RVNC Hedge Fund Activity: Q2 2017 in Review

86 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2017, worth a combined $727M — up 33% from $546M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new RVNC positions and 4 closed out — a net gain of 8 holders — while 37 added to existing stakes and 22 trimmed.

The largest buyer was Franklin Resources, adding an estimated $8.73M. The largest seller was Goldman Sachs, cutting an estimated $8.23M.

  • 86 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2017, up from 78 in Q1 2017.
  • Funds reported $727M of Revance Therapeutics, Inc. stock for Q2 2017, up 33% quarter-over-quarter.
  • 12 funds opened new Revance Therapeutics, Inc. positions in Q2 2017 and 4 closed out, a net change of +8 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q2 2017 was Franklin Resources, an estimated $8.73M added.
  • The largest Revance Therapeutics, Inc. seller in Q2 2017 was Goldman Sachs, an estimated $8.23M sold.

Based on aggregated 13F filings for Q2 2017.